目录
目 录
PREFACE
Chapter 1 Introduction
1.1 Basics of the Human Immune System
1.1.1 The Phagocytes
1.1.2 The Complement System
1.1.3 Acquired Immunity
1.2 Conception of Tumor Immunotherapy
1.3 Progress of Tumor Immunotherapy
1.3.1 Progress of Target Tumor Cells
1.3.2 Progress of Activated Immune Cells [17]
1.4 Clinical Progress in Tumor Immunotherapy
References
Chapter 2 Biomarker of Tumor
2.1 Conception of Biomarker in Tumor
2.2 Role of Biomarker in Tumor
2.2.1 Prediction of Tumor Risk
2.2.2 Tumor Diagnosis
2.2.3 Prediction of Treatment and Post-treatment
2.2.4 Monitoring Tumor Recurrence
2.3 Biomarker of Tumor in Immunotherapy
2.3.1 PD-L1
2.3.2 Tumor Mutation Burden
2.3.3 Mismatch Repair
2.3.4 Microsatellite Instability
2.3.5 Microbiome
References
Chapter 3 Therapeutic Antibody
3.1 Target Immune Cells
3.1.1 Antagonistic Antibodies: Blocking the Suppressors
3.1.2 Agonistic Antibodies: Activating the Effectors
3.2 Target Microenvironment in Tumor
3.2.1 Cancer-associated Fibroblasts (CAFs)
3.2.2 Tumor Vasculature
3.2.3 Bone Marrow-Derived Cells
3.2.4 Extracellular Matrix (ECM)
3.3 Target Solid Tumor
3.3.1 Tumor-Specific Antibodies
3.3.2 Antibody Isotypes in Tumors
3.3.3 Recovering Functional Antitumor Antibodies
References
Chapter 4 Immune Checkpoint Inhibitor
4.1 PD-1/PD-L1 Signal Pathway
4.1.1 Structure and Expression of PD-1
4.1.2 Structure and Expression of PD-Ls
4.1.3 The Mechanism of PD-1/PD-Ls Signaling
4.1.4 Biological Significance of PD-1/PD-L1 Pathway
4.2 PD-1/PD-L1 Inhibitor
4.2.1 Mechanism of Action of PD-1 and PD-L1 Inhibitors
4.2.2 Application of PD-1 and PD-L1 Inhibitors in Cancer
4.3 CTLA-4 Inhibitor
4.3.1 Molecular and Cell Biology of the CTLA-4 Pathway
4.3.2 CD28 and CTLA-4: A Volume Control on T Cell Responses?
4.3.3 Targeting the CTLA-4 Pathway: Lessons from the Clinic
4.4 Other Monoclonal Antibody
4.4.1 Antibodies Currently in Clinical Practice [28]
4.4.2 Monoclonal Antibodies in Clinical Trials [28]
4.5 Adverse Reactions and Management
4.5.1 Adverse Reactions
4.5.2 General Considerations on Monitoring
References(https://www.daowen.com)
Chapter 5 Tumor Vaccine
5.1 Whole-Cell Vaccine
5.2 Polypeptide Vaccine
5.3 Gene Engineering Vaccine
5.4 Nuclei Acid Vaccine
5.4.1 DNA Vaccine
5.4.2 RNA Vaccine
References
Chapter 6 Adaptive T Cell Transfer
6.1 Lymphokine-Activated Killer
6.1.1 NKT
6.1.2 T Cell
6.1.3 Application of LAK
6.2 Tumor Infiltrating Lymphocytes
6.2.1 CD8+ T Cells
6.2.2 CD4+ T Cells
6.3 Natural Killer Cell
6.3.1 Development and Function Maturation of NK Cells
6.3.2 NK Cell Effector Function
6.3.3 NK Cells in Health and Disease
6.4 Cytokine-Induced Killer
6.4.1 What Is CIK?
6.4.2 Ex Vivo Expansion and Alloreactivity of CIK Cells
6.4.3 Biological Characteristics of CIK Cells
6.4.4 Clinical Trials on CIK Cells
6.5 Cytotoxic T Lymphocyte
6.5.1 Activation of CTLs
6.5.2 Cytotoxic T Lymphocytes and Disease
6.6 CAR-T
6.6.1 Structure of CAR-T cells
6.6.2 Production of CAR-T Cells
6.6.3 Clinical development of CAR T Cells
6.6.4 Severe Side Effects and Toxicities
6.7 TCR-T
6.7.1 The Basic Structure and Mechanism of TCR-T Cell
6.7.2 Types of Antigens Used in TCR-T-Cell Therapy
6.7.3 Statistics for Clinical Trials of TCR-T-Cell Therapy
References
Chapter 7 Immune System Modulators
7.1 Cytokine Therapy
7.1.1 Interferon-α
7.1.2 Interleukin-2
7.1.3 Interleukin-15
7.1.4 Interleukin-21
7.1.5 Interleukin-10
7.1.6 Interleukin-12
7.1.7 TNF-α
7.1.8 TGF-β
7.2 Small Molecule Immune Modulators
7.3 Immune Adjuvant
7.3.1 Alum
7.3.2 Microbial Products (TLR agonists)
7.3.3 Archaeosomes
7.3.4 DC-priming Adjuvant
7.4 Indoleamine 2,3-dioxygenase
7.4.1 Structure of Indoleamine 2,3-dioxygenase
7.4.2 Biological Functions of Indoleamine 2,3-dioxygenase
7.4.3 IDO-induced Tumor Immune Escape
7.5 Role of Indoleamine 2,3-dioxygenase Inhibitor [20]
References